3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Thoracic
2
Classical hematology
2
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Venous Thromboembolism
2
Neoplasms
1
Embolism
1
Interventions
Epoetin Alfa
38
Darbepoetin alfa
30
epoetin beta
10
Rivaroxaban
9
olaparib
5
eltrombopag
5
apixaban
5
Heparin, Low-Molecular-Weight
5
pegylated granulocyte colony-stimulating factor
4
pegfilgrastim
4
emicizumab
4
Gemcitabine
4
Filgrastim
4
Dalteparin
4
Cyclophosphamide
4
AP 1903 reagent
4
romiplostim
3
peginesatide
3
luspatercept
3
hetrombopag
3
hematide
3
Vancomycin
3
ON 01910
3
Enoxaparin
3
Azacitidine
3
ACE-011
3
venetoclax
2
telapristone acetate
2
roxadustat
2
iron isomaltoside 1000
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Dabigatran
×
Classical hematology
×
Clear all
NCT04618913
2026-05-26
VICTORIE
Pfizer
Active not recruiting
1 enrolled
NCT03965741
2021-11-30
PRACTISE
Bayer
Completed
97,765 enrolled